Logo

Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry

1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12

  1. Department of Rheumatology, Gaetano Pini Institute, Milan, Italy. maria.manara@gmail.com
  2. Department of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
  3. Department of Rheumatology, Gaetano Pini Institute, Milan, Italy.
  4. Department of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
  5. Rheumatology Unit, L. Sacco University Hospital, Milan, Italy.
  6. Rheumatology Unit, L. Sacco University Hospital, Milan, Italy
  7. Rheumatology and Immunology Unit, Spedali Civili, Brescia, Italy.
  8. Rheumatology and Immunology Unit, Spedali Civili, Brescia, Italy.
  9. Department of Rheumatology, Città della Salute e della Scienza, Torino, Italy.
  10. Rheumatology Unit, Ospedale Mauriziano, Torino, Italy.
  11. Rheumatology Unit, A.S.O. «SS.Antonio e Biagio e C.Arrigo», Alessandria, Italy.
  12. Department of Rheumatology, Gaetano Pini Institute, Milan, Italy.

CER10118 Submission on line
2017 Vol.35, N°5 - PI 0804, PF 0809
Full Papers

Rheumatology Article

 

Abstract

OBJECTIVES:
We aimed to provide data on golimumab real-life use in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) from a multicentre observational registry of Northern Italy.
METHODS:
We extracted data of patients who started treatment with golimumab from October 2010, and who had at least one follow-up visit. Data were analysed until a maximum follow-up of 24 months. The two-year retention rate in the three diseases was assessed with Kaplan-Meier estimators. To compare crude survival between diagnoses and lines of treatment we used the log-rank test, while Cox proportional hazard models were used to adjust for confounders.
RESULTS:
Overall, 410 subjects were included: 180 patients with RA, 110 with PsA and 120 with AS. The two-year retention rate of patients with RA was 47.3%, 48% for PsA, and 62.8% for AS. Crude survival on treatment of patients with AS was significantly higher than that of RA patients (p=0.032), while no significant difference was found between AS and PsA and between RA and PsA. In patients with RA, subjects treated with concomitant sDMARDs showed a lower discontinuation rate than those receiving golimumab alone. The comparison between first and second line of treatment groups did not show any significant difference in mean survival time in patients with RA, PsA and AS.
CONCLUSIONS:
This is the first report of real-life data on two-year survival on treatment with golimumab in RA, PsA and AS. Golimumab showed a similar retention rate when given as first or second line of treatment.

PMID: 28770712 [PubMed]

Received: 23/11/2016 - Accepted : 30/01/2017 - In Press: 27/07/2017 - Published: 15/09/2017